Dermatology Archives - Page 15 of 16

Role of betamethasone valerate 2.250 mg medicated plaster in the treatment of psoriasis and other dermatological pathologies: a review

Sandra Ly MD, Jean Michel Amici MD

Article Type

Review

Published

20 Aug 2018

This review presents the available clinical data from studies with betamethasone valerate medicated plaster in the treatment of psoriasis and other dermatoses and discusses its place in therapy for dermatological conditions.

Cutaneous side effects of molecularly targeted therapies for the treatment of solid tumors

Daniel I G Cubero MD, PhD, Beatrice Martinez Zugaib Abdalla MD, Jean Schoueri, Fabio Iazetti Lopes, Karine Corcione Turke, Jose Guzman MD, Auro Del Giglio MD, PhD, Carlos D’Apparecida Santos Machado Filho MD, PhD, Vanessa Salzano MD, Dolores Gonzalez Fabra MD

Article Type

Review

Published

17 Jul 2018

This article reviews the cutaneous side effects of main molecularly targeted cancer therapies for solid tumors.

Emollient treatment of atopic dermatitis: latest evidence and clinical considerations

Kam Lun Hon MBBS, MD, FAAP, FCCM, Jeng Sum Charmaine Kung BSc, Wing Gi Gigi Ng BSc, Ting Fan Leung MBChB, MD, MRCP, FRCPCH

Article Type

Review

Published

17 Apr 2018

This article reviews current classes of emollients in the market, their clinical evidence in atopic dermatitis and considerations for choice of an emollient.

Atopic dermatitis: a review of topical nonsteroid therapy

Ariana Papier BA, Lindsay C Strowd MD

Article Type

Review

Published

04 Apr 2018

This review focuses on the safety and efficacy of topical calcineurin and PDE4 inhibitors for the treatment of atopic dermatitis.

Treatment with combined dabrafenib and trametinib in BRAF^V600E-mutated metastatic malignant melanoma: a case of long-term complete response after treatment cessation

Sonia Brugnara, Mariacristina Sicher, Elena Maria Bonandini, Davide Donner, Franca Chierichetti, Mattia Barbareschi, Carlo Renè Girardelli, Orazio Caffo

Article Type

Case Report

Published

15 Feb 2018

The case report discusses a patient, diagnosed with BRAFV600E-mutated metastatic malignant melanoma M1a, who achieved a complete metabolic response after 7 months of treatment with the combination of dabrafenib and trametinib.